scholarly article | Q13442814 |
P356 | DOI | 10.1016/J.EJMECH.2013.01.054 |
P953 | full work available at URL | https://api.elsevier.com/content/article/PII:S0223523413000822?httpAccept=text/plain |
https://api.elsevier.com/content/article/PII:S0223523413000822?httpAccept=text/xml | ||
P698 | PubMed publication ID | 23567949 |
P5875 | ResearchGate publication ID | 236139439 |
P2093 | author name string | Saman Raza | |
W. Haq | |||
Arvind K. Srivastava | |||
Daya S. Srivastava | |||
Swayam P. Srivastava | |||
S. B. Katti | |||
P2860 | cites work | Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453) | Q27644265 |
(3-substituted benzyl)thiazolidine-2,4-diones as structurally new antihyperglycemic agents | Q28372550 | ||
A comparison of glycemic control, water retention, and musculoskeletal effects of balaglitazone and pioglitazone in diet-induced obese rats | Q33481431 | ||
GLP-1 for type 2 diabetes | Q33794098 | ||
PPAR-gamma agonists: therapeutic role in diabetes, inflammation and cancer | Q34106716 | ||
Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus | Q34461583 | ||
Adipogenesis: forces that tip the scales | Q34467039 | ||
Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis | Q34686103 | ||
The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes | Q35085591 | ||
Diabetes mellitus: pathogenesis and treatment strategies | Q35855859 | ||
Peroxisome proliferator-activated receptor-gamma calls for activation in moderation: lessons from genetics and pharmacology | Q35975460 | ||
Thiazolidinediones: antidiabetic drugs with cardiovascular effects | Q36715633 | ||
Improved Insulin Resistance and Lipid Metabolism by Cinnamon Extract through Activation of Peroxisome Proliferator-Activated Receptors | Q37014815 | ||
The effect of thiazolidinediones on BMD and osteoporosis | Q37241742 | ||
The genetics of diabetes susceptibility in mice | Q38688754 | ||
Stimulatory effect of Ceriops tagal on hexose uptake in L6 muscle cells in culture. | Q39969825 | ||
Design and synthesis of N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5- methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine [Muraglitazar/BMS-298585], a novel peroxisome proliferator-activated receptor alpha/gamma dual agonist with efficacious gluco | Q40445932 | ||
Troglitazone induces GLUT4 translocation in L6 myotubes. | Q40808543 | ||
Isoxazolidine-3,5-dione and Noncyclic 1,3-Dicarbonyl Compounds as Hypoglycemic Agents | Q41032669 | ||
Indenone derivatives: a novel template for peroxisome proliferator-activated receptor gamma (PPARgamma) agonists | Q42798737 | ||
Novel indole-based peroxisome proliferator-activated receptor agonists: design, SAR, structural biology, and biological activities. | Q42806881 | ||
Novel bisaryl substituted thiazoles and oxazoles as highly potent and selective peroxisome proliferator-activated receptor delta agonists | Q43238006 | ||
Potent antidiabetic effects of rivoglitazone, a novel peroxisome proliferator-activated receptor-gamma agonist, in obese diabetic rodent models | Q43266104 | ||
Structural basis for the structure-activity relationships of peroxisome proliferator-activated receptor agonists | Q44924358 | ||
Dissociation of antihyperglycaemic and adverse effects of partial perioxisome proliferator-activated receptor (PPAR-gamma) agonist balaglitazone | Q46399196 | ||
Indol-1-yl acetic acids as peroxisome proliferator-activated receptor agonists: design, synthesis, structural biology, and molecular docking studies | Q46922580 | ||
Quantitative analysis of pancreatic proinsulin mRNA in genetically diabetic (db/db) mice | Q51630317 | ||
The synthesis of BRL 49653 - a novel and potent antihyperglycaemic agent | Q56384774 | ||
Laboratory animals exhibiting obesity and diabetes syndromes | Q67542769 | ||
Studies on antidiabetic agents. X. Synthesis and biological activities of pioglitazone and related compounds | Q68033178 | ||
Benzyloxazolidine-2,4-diones as potent hypoglycemic agents | Q70156227 | ||
Novel Euglycemic and Hypolipidemic Agents. 1 | Q74511094 | ||
P407 | language of work or name | English | Q1860 |
P921 | main subject | (RS)-rosiglitazone | Q424771 |
P304 | page(s) | 611-620 | |
P577 | publication date | 2013-02-09 | |
P1433 | published in | European Journal of Medicinal Chemistry | Q3008624 |
P1476 | title | Thiazolidin-4-one and thiazinan-4-one derivatives analogous to rosiglitazone as potential antihyperglycemic and antidyslipidemic agents | |
P478 | volume | 63 |
Q38837346 | Dose-related antihyperglycemic and hypolipidemic effects of two novel thiazolidin-4-ones in a rodent model of metabolic syndrome | cites work | P2860 |
Search more.